WINTON GROUP Ltd Takes Position in Charles River Laboratories International, Inc. (NYSE:CRL)

WINTON GROUP Ltd. purchased a new position in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) during the second quarter, according to the company’s most recent Form 13F filing with the SEC. The company bought 2,101 shares of the medical research company’s stock, valued at approximately $434,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of CRL. Vanguard Group Inc. increased its position in shares of Charles River Laboratories International by 1.1% in the first quarter. Vanguard Group Inc. now owns 6,046,467 shares of the medical research company’s stock worth $1,638,290,000 after acquiring an additional 66,161 shares in the last quarter. Clearbridge Investments LLC increased its position in Charles River Laboratories International by 3.1% in the first quarter. Clearbridge Investments LLC now owns 1,513,138 shares of the medical research company’s stock worth $409,985,000 after acquiring an additional 45,079 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in Charles River Laboratories International by 11.9% in the second quarter. Allspring Global Investments Holdings LLC now owns 1,251,618 shares of the medical research company’s stock worth $258,559,000 after purchasing an additional 132,802 shares during the period. Meritage Group LP increased its holdings in Charles River Laboratories International by 2.3% in the first quarter. Meritage Group LP now owns 1,182,268 shares of the medical research company’s stock worth $320,336,000 after purchasing an additional 26,892 shares in the last quarter. Finally, Earnest Partners LLC increased its position in shares of Charles River Laboratories International by 0.5% in the first quarter. Earnest Partners LLC now owns 893,761 shares of the medical research company’s stock worth $242,165,000 after purchasing an additional 4,393 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s shares.

Charles River Laboratories International Price Development

Shares of NYSE:CRL opened at $206.21 on Wednesday. The stock has a market cap of $10.62 billion, a price/earnings ratio of 24.26, a price/earnings/growth ratio of 3.89 and a beta of 1.36. The company has a 50-day moving average of $209.42 and a 200-day moving average of $225.08. Charles River Laboratories International, Inc. has a 52-week low of $161.65 and a 52-week high of $275.00. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.58 and a quick ratio of 1.21.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last released its earnings results on Wednesday, August 7. The medical research company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.39 by $0.41. Charles River Laboratories International had a return on equity of 14.96% and a net margin of 10.83%. The company had revenue of $1.03 billion during the quarter, compared to analysts’ estimates of $1.03 billion. On average, equities research analysts predict that Charles River Laboratories International, Inc. will post 10.01 EPS for the current fiscal year.

Charles River Laboratories International announced that its board of directors initiated a stock repurchase plan on Wednesday, August 7, that will allow the company to repurchase up to $1.00 billion of its outstanding shares. This repurchase authorization allows the medical research company to repurchase up to 9.6% of its shares through open market purchases. Stock repurchase plans are typically an indication that a company’s board of directors believes its stock is undervalued.

Wall Street analysts weigh in

Several research analysts have recently weighed in on CRL stock. Evercore ISI lowered their price target on shares of Charles River Laboratories International from $265.00 to $225.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. Robert W. Baird lowered shares of Charles River Laboratories International from an “outperform” rating to a “neutral” rating and lowered their price target on shares of Charles River Laboratories International from $239.00 to $191.00 in a report on Thursday, August 8th. Barclays lowered their price target on shares of Charles River Laboratories International from $230.00 to $210.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 8th. UBS Group lowered their price target on shares of Charles River Laboratories International from $290.00 to $240.00 and set a “buy” rating for the company in a research note on Thursday, August 8th. Finally, Mizuho took on shares of Charles River Laboratories International in a research note on Friday, June 7th. They gave a “neutral” rating and a $235.00 price target on the stock. Ten equities analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the firm currently has an average rating of “Hold” and a consensus price target of $231.00.

Read our latest report on CRL

Company Profile of Charles River Laboratories International

(Free Report)

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development and safety testing services in the United States, Europe, Canada, Asia Pacific and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Solutions (Manufacturing).

Featured Stories

Would you like to know which other hedge funds have CRL in their portfolio? Visit HoldingsChannel.com for the latest 13F filings and insider transactions for Charles River Laboratories International, Inc. (NYSE:CRL – Free Report).

Get news and reviews for Charles River Laboratories International Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings on Charles River Laboratories International and related companies with MarketBeat.com’s FREE daily email newsletter.